Results 181 to 190 of about 181,705 (382)

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

open access: yesCirculation, 2016
J. Gillmore   +31 more
semanticscholar   +1 more source

Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow   +4 more
wiley   +1 more source

Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies

open access: yesOrphanet Journal of Rare Diseases
Transthyretin amyloidosis (ATTR) is a severe and rare disease characterized by the progressive deposition of misfolded transthyretin proteins, causing irreversible organ damage.
Bérénice Hebrard   +28 more
doaj   +1 more source

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

open access: yesJournal of Nuclear Cardiology, 2019
S. Dorbala   +25 more
semanticscholar   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata   +19 more
wiley   +1 more source

Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage

open access: yesEuropean Journal of Heart Failure, EarlyView.
Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy   +4 more
wiley   +1 more source

Familial Mediterranean fever in northwest of Iran (Ardabil): The first global report from Iran [PDF]

open access: yes
Familial Mediterranean fever (FMF), which is the prototype of the hereditary periodic fever syndromes, is common in the countries around the Mediterranean Sea. Considering its geographical position in the northwest of Iran, with its population of Turkish
امامی, دینا   +10 more
core  

Amyloidosis in paraplegia [PDF]

open access: bronze, 1963
Alessia Maglio, P Potenza
openalex   +1 more source

Sex‐based differences in heart failure management and outcomes: Insights from the French‐DataHF cohort

open access: yesEuropean Journal of Heart Failure, EarlyView.
Sex differences in heart failure (HF) management and outcomes in the French‐DataHF cohort. CI, confidence interval; HFH, heart failure hospitalization; HR, hazard ratio; IPW, inverse probability weighting; KM, Kaplan–Meier; LD, loop diuretic; RAS, renin–angiotensin system; RASi, renin–angiotensin system inhibitor.
Guillaume Baudry   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy